OnDemand Cornea Update (10/29/22) - Feat. Peter R. and Ruth Laibson Endowed Lecture

Wednesday, November 2, 2022, 9:44 AM - Thursday, November 2, 2023, 11:00 PM


AMA PRA Category 1 Credits™ (4.00 hours), ABO MOC Part II (4.00 hours), Non-Physician Attendance (4.00 hours)

With the emergence of new technologies, treatments, and clinical trial results, ophthalmologists need to understand how to incorporate these advances into clinical care. We will discuss latest advances in the management of inherited and acquired ophthalmic diseases and evidence for emerging therapies and screening modalities. Both didactic and case-based educational formats will be utilized to illustrate current trends in the management of complex and routine ophthalmic patients, taking into account diagnostics as well as nonsurgical and surgical treatment.

1. Discuss important new advances in the etiologies, diagnosis, and treatment/prevention of eye diseases.
2. Identify basic and clinical vision research that can be transformed into improved clinical care.
3. Assess the role of new technologies in the evaluation and treatment of eye diseases.
4. Describe factors that impact the effective delivery of the highest quality eye care for the public.
5. Identify clinical, scientific, and ethical issues confronting the profession.
6. Obtain information and tools through multiple facets to help ophthalmologists deliver high and efficient quality of care.

AMA PRA Statement
Wills Eye Hospital designates this Enduring Material educational activity for a maximum of 4.00 AMA PRA Category 1 Credits^TM. Physicians should only claim the credit commensurate with the extent of their participation in the activity.

Click Here to view the full list of disclosures.

Mitigation of Relevant Financial Relationships

In compliance with the Standards for Integrity and Independence in Accredited Continuing Education set by the Accreditation Council for Continuing Medical Education (ACCME), it is the policy of Wills Eye Hospital that the information presented at CME activities will be commercially unbiased and based upon clinical and scientific evidence. To help participants make judgments about the presence of commercial bias, Wills Eye Hospital provides information that all individuals in a position to control the content of a CME activity (including faculty, planners, reviewers or others) have disclosed about all financial relationships they have with ineligible companies. All relevant financial relationships have been mitigated.

Ineligible companies are companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. Financial relationships are relevant if the educational content an individual can control is related to the business lines or products of the ineligible company. The CME activity staff at Wills Eye Hospital report no financial relationships with ineligible companies.